Activism: latest news

Activism features

Activism in your own words

Activism news from aidsmap

More news

Activism news selected from other sources

  • When We Rise: The exclusive interview with AIDS activist & author Cleve Jones

    Cleve Jones is an American human rights activist, author and lecturer whose work has spanned more than three decades. I had the opportunity to sit down with Jones to pick his brain about sex in San Francisco before AIDS, founding San Francisco AIDS Foundation, and how activists can take action with an incoming Donald Trump administration.

    02 December 2016 | BETA blog
  • The Fight for HIV Travel Insurance Cover

    How a ten year battle to get travel cover for HIV patients changed the face of medical travel insurance.

    02 December 2016 | World First
  • World AIDS Day: What We're Grateful For

    On this World AIDS Day, AVAC is drawing strength, as we always do, from our partners and from these issues, individuals and developments that shine light on the road ahead.

    02 December 2016 | AVAC
  • Trump leaves AIDS advocates feeling anxious

    The election of Donald Trump has left many people with HIV, their medical providers, and advocates feeling uncertain and anxious. Although Trump said little about HIV during the presidential campaign, his opposition to the Affordable Care Act and his conservative Cabinet picks suggest many of the advances of the Obama years may be rolled back. But all agreed that it is hard to predict specific details.

    01 December 2016 | Bay Area Reporter
  • The reinvention of radical protest: life on the frontline of the Aids epidemic

    An extract from David France's new book How to Survive a Plague.

    29 November 2016 | The Guardian
  • The AIDS Fight: Andrew Sullivan on a History of the Movement

    A question has always hung over the reaction of gay men to the plague that terrorized and decimated them in the 1980s and 1990s: Why did they not surrender? David France’s remarkable book tries to answer that question.

    22 November 2016 | New York Times
  • Community demand for temporary halt to Gilead DISCOVER study

    A group of U.S., Canadian, and European community advocates and HIV NGO workers have written a letter exrpesing "deep dismay" that Gilead Sciences have proceeded with the DISCOVER trial PrEP"without engaging stakeholders in a substantial or meaningful way.". DISCOVER will compared Gilead's new comination pill, Descovy against Truvada as PrEP. In 2007, the HIV/AIDS field adopted Good Participatory Practice (GPP), a formal set of guidelines approved by UNAIDS for stakeholder engagement in HIV prevention clinical trials. "It is astonishing," says the letter, "that Gilead has failed to follow GPP guidelines in the design and implementation of DISCOVER, since GPP was developed partly as a response to the failure of previous prevention trials involving tenofovir."

    17 November 2016 | HIV Prevention Justice Alliance
  • Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?

    Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials.

    17 November 2016 | The Body
  • Statement on DISCOVER Study of F/TAF for PrEP

    Gilead Sciences released this statement after considerable interest and concerns abut the forthcoming study of their new tenofovir formulation, TAF, for use in PrEP. The TAF/FTC pill is called Descovy(R). "Gilead Sciences is sponsoring a clinical trial, known as the DISCOVER study, to test whether a combination of emtricitabine and tenofovir alafenamide (F/TAF) is as safe and effective as Truvada® (emtricitabine and tenofovir disoproxil fumarate, F/TDF) at reducing the risk of HIV infection when used as pre-exposure prophylaxis (PrEP). F/TAF was recently approved for HIV treatment, but it is not yet known whether it is effective as PrEP...."

    16 November 2016 | Gilead Sciences
  • What the HIV/AIDS Community Is Saying About the 2016 Election Results

    Trump did not mention HIV/AIDS in his campaign speeches and platform. What does this mean in terms of fighting the epidemic during the next four years? Below we compile a list of comments and press releases from HIV advocates and AIDS service organizations.

    10 November 2016 | Poz
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.